Nice, France

Oleksandr Grytsai

This inventor holds 1 USPTO granted patent and 1 published patent application. Top assignees: Centre National De La Recherche Scientifique, National Institute of Health and Medical Research, Université Cote D'azur. Active years: 2022.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Oleksandr Grytsai. Retrieved from https://idiyas.com/inventor/oleksandr-grytsai

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 1 

% Patents Active = 100.0

Average Co-Inventor Count = 6.0

ph-index = 1


Company Filing History:


Years Active: 2022

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Oleksandr Grytsai: Innovator in Cancer Treatment

Introduction

Oleksandr Grytsai is a notable inventor based in Nice, France. He has made significant contributions to the field of cancer treatment through his innovative research and development of pharmaceutical compounds. His work focuses on the creation of biguanide derivatives, which hold promise in the fight against cancer, particularly melanoma.

Latest Patents

Grytsai holds a patent for "Biguanide derivatives and their rearrangement products for use in the treatment of cancer." This patent describes biguanide derivatives of formula (I) and their rearrangement products. The compounds outlined in this patent are intended for use in methods for treating cancer, specifically targeting melanoma.

Career Highlights

Throughout his career, Oleksandr Grytsai has worked with prestigious research institutions, including the Centre National de la Recherche Scientifique and the Institut National de la Santé et de la Recherche Médicale. His experience in these organizations has allowed him to advance his research and contribute to significant scientific advancements.

Collaborations

Grytsai has collaborated with esteemed colleagues such as Rachid Benhida and Stephane Rocchi. These partnerships have fostered a collaborative environment that enhances the potential for innovative breakthroughs in cancer treatment.

Conclusion

Oleksandr Grytsai's work in developing biguanide derivatives represents a significant advancement in cancer treatment. His contributions to the field, along with his collaborations, highlight the importance of innovation in medical research.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…